BRAINLIFE.ORG





Topics


Glioblastoma | Treatment | Immunotherapy | Dendritic-cell-based vaccine






Home > Publications > Topics > Glioblastoma > Treatment > Immunotherapy > Dendritic cells






*Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE 2nd, Lally-Goss D, McGehee-Norman S, Paolino A, Reardon DA, Friedman AH, Friedman HS, Bigner DD.
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.
Mol Cancer Ther. 2009 Oct 12;8(10):2773-9. doi: 10.1158/1535-7163.MCT-09-0124. PMID: 19825799. Interventional study. ˍ




Ridolfi L, Gurrieri L, Riva N, Bulgarelli J, De Rosa F, Guidoboni M, Fausti V, Ranallo N, Calpona S, Tazzari M, Petrini M, Granato AM, Pancisi E, Foca F, D'Allagata M, Bondi I, Amadori E, Cortesi P, Zani C, Ancarani V, Gamboni A, Polselli A, Pasini G, Bartolini D, Maimone G, Arpa D, Tosatto L.
First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax).
Front Immunol. 2024 Aug 13;15:1404861. doi: 10.3389/fimmu.2024.1404861. PMID: 39192978. Interventional study. ˍ




*Wong CE, Chang Y, Chen PW, Huang YT, Chang YC, Chiang CH, Wang LC, Lee PH, Huang CC, Hsu HJ, Lee JS.
Dendritic cell vaccine for glioblastoma: an updated meta-analysis and trial sequential analysis.
J Neurooncol. 2024 Aug 21. doi: 10.1007/s11060-024-04798-w. PMID: 39167243. Meta-analysis˰ ˍ